<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67308">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02133339</url>
  </required_header>
  <id_info>
    <org_study_id>TRN-157-101</org_study_id>
    <nct_id>NCT02133339</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study of TRN-157 in Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Nebulized, TRN-157 Inhalation Solution in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theron Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theron Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single ascending dose study is to determine and evaluate the safety and tolerability of
      TRN-157 in approximately 40 healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability as determined by number of subjects with adverse events</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Area Under the Plasma Concentration-Time Curve from Zero to the Time of the Last Measurable Concentration (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Area Under the Plasma Concentration-Time Curve from Zero to Infinity (AUC0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time to Peak Plasma Concentration (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Half-Life (t½)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Elimination Rate Constant (kel)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Volume of Distribution at Steady State after Non-IV Administration (Vss/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Total Plasma Clearance after Non-IV Administration (CL/F)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>TRN-157</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRN-157</intervention_name>
    <arm_group_label>TRN-157</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has provided written informed consent

          2. The subject is male or female 18 to 65 years of age

          3. If the subject or subject's partner is of childbearing potential, a medically
             acceptable form of contraception will be

          4. Non-smoker

          5. Good general health

          6. Willing to abstain from alcohol, caffeine, and xanthine-containing beverages

          7. The subject is compliant and available throughout the entire study period

        Exclusion Criteria:

          1. Current diagnosis, as per subject or investigator or screening assessment, of:

               1. unstable or uncontrolled disease in any organ system (including cardiovascular)
                  on present therapy

               2. history of narrow angle glaucoma

               3. history of alcohol abuse within the past 5 years

               4. history of smoking within the past 6 months

               5. positive result for the alcohol and/or drugs of abuse

               6. weight &gt; 100 kg or &lt; 50 kg

               7. clinically significant abnormal ECG

               8. history of clinically significant (per the Investigator) disease or disorder

               9. any clinically significant abnormalities in clinical chemistry, hematology, or
                  urinalysis results

              10. Abnormal vital signs defined as any of the following:

                    -  Systolic blood pressure ≥ 140 mmHg

                    -  Diastolic blood pressure ≥ 90mmHg

          2. Heart rate &lt; 40 or &gt; 85 beats per minute

          3. Fever or other clinically significant physical exam findings

          4. Current or history of clinically significant respiratory disease, including asthma,
             emphysema, chronic bronchitis, or cystic fibrosis

          5. History or current symptom(s) of respiratory tract inflammation

          6. Inability to perform reproducible spirometry in accordance with American  Thoracic
             Society (ATS) guidelines

          7. Abnormal FEV1, FVC, or FEV1/FVC (FEV1 or FVC &lt; 80% of predicted or FEV1/FVC ratio &lt;
             0.7)

          8. FEV1 variability &gt; 10% between study visits

          9. Female of childbearing potential with a positive serum pregnancy test or currently
             breastfeeding

         10. Currently being treated for hypertension or taking any other medications that affect
             blood pressure significantly

         11. Inability to perform acceptable, quality serial spirometry or any other study
             procedures

         12. Positive screen for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody, or HIV
             antibody
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joe Oren</last_name>
    <role>Study Director</role>
    <affiliation>Theron Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet Diehl</last_name>
    <phone>866-585-7823</phone>
    <phone_ext>102</phone_ext>
    <email>jdiehl@theronpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>May 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
